Valuation: Adaptive Biotechnologies Corporation

Market Cap 3.92B 3.39B 3.19B 2.89B 5.44B 376B 5.52B 37.36B 14.64B 188B 14.72B 14.4B 626B P/E 2026 *
-45.1x
P/E 2027 * -139x
Enterprise Value 3.86B 3.33B 3.14B 2.85B 5.36B 370B 5.44B 36.8B 14.42B 185B 14.49B 14.18B 616B EV / Sales 2026 *
13.2x
EV / Sales 2027 * 10.6x
Free-Float
97.85%
Yield 2026 *
-
Yield 2027 * -
1 day-0.85%
1 week-3.27%
Current month+8.82%
1 month+7.16%
3 months+93.23%
6 months+54.76%
Current year+51.23%
1 week 23.92
Extreme 23.92
25.64
1 month 20.9
Extreme 20.9
26.16
Current year 12
Extreme 12
26.16
1 year 12
Extreme 12
26.16
3 years 2.28
Extreme 2.28
26.16
5 years 2.28
Extreme 2.28
40
10 years 2.28
Extreme 2.28
71.25
Manager TitleAgeSince
Chief Executive Officer 51 08/09/2009
Director of Finance/CFO 42 08/04/2024
President 54 01/02/2018
Director TitleAgeSince
Chairman 51 -
Director/Board Member 63 01/02/2013
Director/Board Member 70 01/12/2013
Date Insider Type Main position Quantity % Market Cap.
8/10/26 A Sell

Executive/Senior Manager

-3,000 0.0019%
7/30/26 A Sell

Executive/Senior Manager

-1,299 0.0008%
7/21/26 A Fiscal year

Founder

1,062,000 0.6636%
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%-3.27%+97.90%+294.86% 3.92B
-3.33%-12.35%+35.28%+64.10% 3.27B
-0.99%+8.32%+181.20%+15.82% 3.18B
-0.43%-2.22%+289.70%+449.11% 2.39B
-1.68%-5.23%-25.35%-27.61% 2.23B
-0.43%-3.67%+9.37% - 1.52B
-5.75%-6.91%+7.83%+44.98% 977M
+1.06%-1.20%+123.35%-43.22% 855M
-1.24%-2.99%-35.12%-2.85% 555M
-11.56%-1.10%+8.62%+270.60% 545M
Average -2.43%-2.37%+69.28%+118.42% 1.94B
Weighted average by Cap. -1.62%-2.51%+93.85%+143.96%

Financials

2026 *2027 *
Net sales 293M 253M 238M 217M 407M 28.1B 413M 2.8B 1.1B 14.05B 1.1B 1.08B 46.81B 359M 310M 291M 265M 498M 34.35B 505M 3.42B 1.34B 17.18B 1.35B 1.32B 57.23B
Net income -85.78M -74.09M -69.71M -63.35M -119M -8.22B -121M -818M -320M -4.11B -322M -315M -13.69B -27.55M -23.8M -22.39M -20.35M -38.27M -2.64B -38.83M -263M -103M -1.32B -103M -101M -4.4B
Net Debt -58.99M -50.95M -47.94M -43.57M -81.95M -5.65B -83.15M -562M -220M -2.83B -221M -217M -9.42B -104M -89.68M -84.38M -76.69M -144M -9.95B -146M -990M -388M -4.98B -390M -381M -16.57B
Logo Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
Employees
624
Date Price Change Volume
18/08/26 $24.56 -0.85% 1,878,377
17/08/26 $24.77 +0.12% 2,668,386
14/08/26 $24.74 +1.14% 1,743,593
13/08/26 $24.46 -3.13% 1,537,646
12/08/26 $25.25 -0.55% 1,706,891
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
24.56USD
Average target price
25.07USD
Spread / Average Target
+2.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ADPT Stock